These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 24394185)
1. Effective intravenous therapy for neurodegenerative disease with a therapeutic enzyme and a peptide that mediates delivery to the brain. Meng Y; Sohar I; Sleat DE; Richardson JR; Reuhl KR; Jenkins RB; Sarkar G; Lobel P Mol Ther; 2014 Mar; 22(3):547-553. PubMed ID: 24394185 [TBL] [Abstract][Full Text] [Related]
2. A Hitchhiker's guide to the blood-brain barrier: in trans delivery of a therapeutic enzyme. Sands MS Mol Ther; 2014 Mar; 22(3):483-484. PubMed ID: 24584077 [No Abstract] [Full Text] [Related]
3. A Basic ApoE-Based Peptide Mediator to Deliver Proteins across the Blood-Brain Barrier: Long-Term Efficacy, Toxicity, and Mechanism. Meng Y; Wiseman JA; Nemtsova Y; Moore DF; Guevarra J; Reuhl K; Banks WA; Daneman R; Sleat DE; Lobel P Mol Ther; 2017 Jul; 25(7):1531-1543. PubMed ID: 28456380 [TBL] [Abstract][Full Text] [Related]
4. Lysosomal protein thermal stability does not correlate with cellular half-life: global observations and a case study of tripeptidyl-peptidase 1. Collier AM; Nemtsova Y; Kuber N; Banach-Petrosky W; Modak A; Sleat DE; Nanda V; Lobel P Biochem J; 2020 Feb; 477(3):727-745. PubMed ID: 31957806 [TBL] [Abstract][Full Text] [Related]
5. Intrathecal tripeptidyl-peptidase 1 reduces lysosomal storage in a canine model of late infantile neuronal ceroid lipofuscinosis. Vuillemenot BR; Katz ML; Coates JR; Kennedy D; Tiger P; Kanazono S; Lobel P; Sohar I; Xu S; Cahayag R; Keve S; Koren E; Bunting S; Tsuruda LS; O'Neill CA Mol Genet Metab; 2011 Nov; 104(3):325-37. PubMed ID: 21784683 [TBL] [Abstract][Full Text] [Related]
6. Systemic administration of tripeptidyl peptidase I in a mouse model of late infantile neuronal ceroid lipofuscinosis: effect of glycan modification. Meng Y; Sohar I; Wang L; Sleat DE; Lobel P PLoS One; 2012; 7(7):e40509. PubMed ID: 22792360 [TBL] [Abstract][Full Text] [Related]
7. From gut to brain: bioencapsulated therapeutic protein reduces amyloid load upon oral delivery. Mäger I; Roberts TC; Wood MJ; El Andaloussi S Mol Ther; 2014 Mar; 22(3):485-486. PubMed ID: 24584078 [No Abstract] [Full Text] [Related]
8. Gemfibrozil, food and drug administration-approved lipid-lowering drug, increases longevity in mouse model of late infantile neuronal ceroid lipofuscinosis. Ghosh A; Rangasamy SB; Modi KK; Pahan K J Neurochem; 2017 May; 141(3):423-435. PubMed ID: 28199020 [TBL] [Abstract][Full Text] [Related]
9. Large-volume intrathecal enzyme delivery increases survival of a mouse model of late infantile neuronal ceroid lipofuscinosis. Xu S; Wang L; El-Banna M; Sohar I; Sleat DE; Lobel P Mol Ther; 2011 Oct; 19(10):1842-8. PubMed ID: 21730969 [TBL] [Abstract][Full Text] [Related]
10. Upregulation of tripeptidyl-peptidase 1 by 3-hydroxy-(2,2)-dimethyl butyrate, a brain endogenous ligand of PPARα: Implications for late-infantile Batten disease therapy. Chakrabarti S; Chandra S; Roy A; Dasarathi S; Kundu M; Pahan K Neurobiol Dis; 2019 Jul; 127():362-373. PubMed ID: 30928643 [TBL] [Abstract][Full Text] [Related]
11. Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis. Chang M; Cooper JD; Sleat DE; Cheng SH; Dodge JC; Passini MA; Lobel P; Davidson BL Mol Ther; 2008 Apr; 16(4):649-56. PubMed ID: 18362923 [TBL] [Abstract][Full Text] [Related]
12. TPP1 Delivery to Lysosomes with Extracellular Vesicles and their Enhanced Brain Distribution in the Animal Model of Batten Disease. Haney MJ; Klyachko NL; Harrison EB; Zhao Y; Kabanov AV; Batrakova EV Adv Healthc Mater; 2019 Jun; 8(11):e1801271. PubMed ID: 30997751 [TBL] [Abstract][Full Text] [Related]
13. Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosis. Vuillemenot BR; Kennedy D; Cooper JD; Wong AM; Sri S; Doeleman T; Katz ML; Coates JR; Johnson GC; Reed RP; Adams EL; Butt MT; Musson DG; Henshaw J; Keve S; Cahayag R; Tsuruda LS; O'Neill CA Mol Genet Metab; 2015 Feb; 114(2):281-93. PubMed ID: 25257657 [TBL] [Abstract][Full Text] [Related]
14. Glial fibrillary acidic protein is elevated in the lysosomal storage disease classical late-infantile neuronal ceroid lipofuscinosis, but is not a component of the storage material. Xu S; Sleat DE; Jadot M; Lobel P Biochem J; 2010 May; 428(3):355-62. PubMed ID: 20370715 [TBL] [Abstract][Full Text] [Related]
15. Inducible transgenic expression of tripeptidyl peptidase 1 in a mouse model of late-infantile neuronal ceroid lipofuscinosis. Nemtsova Y; Wiseman JA; El-Banna M; Lobel P; Sleat DE PLoS One; 2018; 13(2):e0192286. PubMed ID: 29408933 [TBL] [Abstract][Full Text] [Related]
17. Enzyme replacement therapy delays pupillary light reflex deficits in a canine model of late infantile neuronal ceroid lipofuscinosis. Whiting RE; Narfström K; Yao G; Pearce JW; Coates JR; Castaner LJ; Jensen CA; Dougherty BN; Vuillemenot BR; Kennedy D; O'Neill CA; Katz ML Exp Eye Res; 2014 Aug; 125():164-72. PubMed ID: 24954537 [TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl-peptidase I does not functionally compensate for the loss of tripeptidyl-peptidase I in the neurodegenerative disease late-infantile neuronal ceroid lipofuscinosis. Kim KH; Pham CT; Sleat DE; Lobel P Biochem J; 2008 Oct; 415(2):225-32. PubMed ID: 18570628 [TBL] [Abstract][Full Text] [Related]